Fulgent Genetics (FLGT)
(Delayed Data from NSDQ)
$17.31 USD
-0.48 (-2.70%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $17.32 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.31 USD
-0.48 (-2.70%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $17.32 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Is FULGENT GENETIC (FLGT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (FLGT) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for February 24th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 24th
FULGENT GENETIC (FLGT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
FULGENT GENETIC (FLGT) closed at $170.98 in the latest trading session, marking a -0.86% move from the prior day.
Top Ranked Momentum Stocks to Buy for February 9th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 9th.
Earnings Estimates Rising for FULGENT GENETIC (FLGT): Will It Gain?
by Zacks Equity Research
FULGENT GENETIC (FLGT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Are You Looking for a Top Momentum Pick? Why FULGENT GENETIC (FLGT) is a Great Choice
by Zacks Equity Research
Does FULGENT GENETIC (FLGT) have what it takes to be a top stock pick for momentum investors? Let's find out.
FULGENT GENETIC (FLGT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
FULGENT GENETIC (FLGT) closed the most recent trading day at $70, moving +1.1% from the previous trading session.
FULGENT GENETIC (FLGT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
FULGENT GENETIC (FLGT) closed at $69.07 in the latest trading session, marking a -1.1% move from the prior day.
Fulgent Genetics' (FLGT) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Fulgent Genetics (FLGT).
4 MedTech Stocks Up More Than 100% in 2020 With Room to Run
by Urmimala Biswas
We discuss four MedTech stocks, CDNA, FLGT, OMI and QDEL that more than doubled in 2020, and are poised to maintain market beating momentum in 2021 on strong fundamentals.
Zacks.com featured highlights include: Winnebago, General Motors, 360 DigiTech, Fulgent Genetics and Ally Financial
by Zacks Equity Research
Zacks.com featured highlights include: Winnebago, General Motors, 360 DigiTech, Fulgent Genetics and Ally Financial
5 High Earnings Yield Bets Amid an Uncertain Santa Rally
by Rimmi Singhi
Check out these five high earnings yield stocks that can make you rich, irrespective of the Santa rally or a year-end pullback.
Health Catalyst (HCAT) Catches Eye: Stock Jumps 5.1%
by Zacks Equity Research
Health Catalyst (HCAT) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: Addus HomeCare, Fulgent Genetics and Hologic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Addus HomeCare, Fulgent Genetics and Hologic
3 MedTech Growth Stocks With Solid Prospects for 2021
by Zacks Equity Research
Here are a few MedTech growth stocks poised for a rebound that investors can scoop up to reap profits going into 2021.
Top Ranked Momentum Stocks to Buy for December 10th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 10th
Omnicell (OMCL) Looks Good: Stock Adds 5% in Session
by Zacks Equity Research
Omnicell (OMCL) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Senseonics Holdings (SENS) Surges: Stock Moves 5.2% Higher
by Zacks Equity Research
Senseonics Holdings (SENS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Wall Street Regains Momentum on Vaccine Hopes: 5 Top Picks
by Nalak Das
Investment in momentum stocks with a favorable Zacks Rank may be fruitful in the near term. These include Fulgent Genetics (FLGT), II-VI (IIVI), General Motors (GM), Flagstar Bancorp (FBC) and Lear (LEA).
Top Ranked Momentum Stocks to Buy for November 17th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 17th
Illumina-CDGN Partner to Create Coronavirus Tracking System
by Zacks Equity Research
Illumina (ILMN) partners with Australia's CDGN to track the national transmission of the virus causing COVID-19.
Strength Seen in Fulgent Genetics (FLGT): Stock Soars 11.6%
by Zacks Equity Research
Fulgent Genetics (FLGT) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.
Zacks.com featured highlights include: Fulgent Genetics, Primoris Services, Niu Technologies, Surface Oncology and Aldeyra Therapeutics
by Zacks Equity Research
Zacks.com featured highlights include: Fulgent Genetics, Primoris Services, Niu Technologies, Surface Oncology and Aldeyra Therapeutics
5 Stocks to Buy as Analysts Initiate Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Earnings Estimates Moving Higher for FULGENT GENETIC (FLGT): Time to Buy?
by Zacks Equity Research
FULGENT GENETIC (FLGT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.